Management of febrile neutropenia: consensus of the Brazilian Association of Hematology, Blood Transfusion and Cell Therapy - ABHH

IF 1.6 Q3 HEMATOLOGY Hematology, Transfusion and Cell Therapy Pub Date : 2024-12-01 DOI:10.1016/j.htct.2024.11.119

Marcio Nucci , Celso Arrais-Rodrigues , Maria Daniela Bergamasco , Marcia Garnica , Ana Beatriz Firmato Gloria , Mariana Guarana , Clarisse Machado , Jessica Ramos , Marco Aurelio Salvino , Belinda Simões

{"title":"Management of febrile neutropenia: consensus of the Brazilian Association of Hematology, Blood Transfusion and Cell Therapy - ABHH","authors":"Marcio Nucci , Celso Arrais-Rodrigues , Maria Daniela Bergamasco , Marcia Garnica , Ana Beatriz Firmato Gloria , Mariana Guarana , Clarisse Machado , Jessica Ramos , Marco Aurelio Salvino , Belinda Simões","doi":"10.1016/j.htct.2024.11.119","DOIUrl":null,"url":null,"abstract":"<div><div>Febrile neutropenia is a major complication of the treatment of patients with hematologic diseases. Recent epidemiologic changes, with an increase in infection caused by drug-resistant bacteria, represent a major challenge for the proper management of febrile neutropenia. The impact of these changes in the epidemiology of infection may vary according to the region. In this document we present recommendations from the Infectious Diseases Committee of the Brazilian Association of Hematology, Blood Transfusion and Cell Therapy (ABHH) for the management of febrile neutropenia in hematologic patients. The consensus was developed by ten experts in the field, using the Delphi methodology. In the document we provide recommendations for the initial workup, prophylaxis, empiric antibiotic and antifungal therapy, modifications in the empiric regimen and criteria for discontinuing antimicrobial therapy.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"46 ","pages":"Pages S346-S361"},"PeriodicalIF":1.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726106/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology, Transfusion and Cell Therapy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2531137924029754","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Febrile neutropenia is a major complication of the treatment of patients with hematologic diseases. Recent epidemiologic changes, with an increase in infection caused by drug-resistant bacteria, represent a major challenge for the proper management of febrile neutropenia. The impact of these changes in the epidemiology of infection may vary according to the region. In this document we present recommendations from the Infectious Diseases Committee of the Brazilian Association of Hematology, Blood Transfusion and Cell Therapy (ABHH) for the management of febrile neutropenia in hematologic patients. The consensus was developed by ten experts in the field, using the Delphi methodology. In the document we provide recommendations for the initial workup, prophylaxis, empiric antibiotic and antifungal therapy, modifications in the empiric regimen and criteria for discontinuing antimicrobial therapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

发热性中性粒细胞减少症的管理：巴西血液学、输血和细胞治疗协会的共识。

发热性中性粒细胞减少症是血液病患者治疗的主要并发症。最近的流行病学变化，耐药细菌引起的感染增加，对发热性中性粒细胞减少症的适当管理提出了重大挑战。这些变化对感染流行病学的影响可能因区域而异。在本文中，我们提出了巴西血液学、输血和细胞治疗协会（ABHH）传染病委员会对血液学患者发热性中性粒细胞减少症管理的建议。该共识是由该领域的10位专家使用德尔菲方法制定的。在该文件中，我们提供了初步检查、预防、经验性抗生素和抗真菌治疗、修改经验性方案和停止抗菌治疗标准的建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊